Our study demonstrated that pERK and pAKT expression was significantly reduced in dasatinib‐treated patients compared to imatinib‐ and nilotinib‐treated patients and dasatinib's inhibitory effect on them was closely associated with the mobilization of cytotoxic lymphocytes, but this effect seemed to be linked to a prior history of CMV infection. This evidence concerns the gene EIF2AK3 and cytomegalovirus infection.